oral glp-1 medications fda approved Semaglutide Gets Approval for CV Event Reduction in High-risk Diabetes Patients A new chapter in GLP-1
Description
GLP-1 has the following actions: (1) slows gastric emptying
The absence from the drug label does not mean the connection is not real
Participants completed original and adapted forms of validated assessments (see Supplemental document)
Therefore, practitioners should exercise caution when considering combination approaches, particularly for patients with existing cardiovascular risk factors
